Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.

Baricitinib effectively promotes hair regrowth in both scalp and nonscalp areas for alopecia areata universalis patients.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

JAK inhibitors show promise in effectively treating hair loss from alopecia areata.

Jujube fruit extract may reduce kidney damage from ibuprofen in rats.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.

Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.

New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

JAK inhibition may help manage autoimmune conditions in Down syndrome.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Targeting ornithine decarboxylase can help prevent skin cancer.

Different tumor cells in one basal cell carcinoma can cause mixed treatment responses, suggesting personalized treatment is needed.

New therapies for Birt–Hogg–Dubé syndrome are being developed based on understanding the FLCN gene's role.

MVP treatment is effective and safe for recurrent breast cancer.

CDK4/6 inhibitors may cause hair loss in breast cancer patients.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

Genetic testing is crucial for diagnosing and managing non-Herlitz junctional epidermolysis bullosa.

Sirolimus effectively reduces lesions and improves quality of life in Blue Rubber Bleb Nevus Syndrome with manageable side effects.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.